Navigation Links
NeoStem Announces NY State License for Adult Stem Cell Collection
Date:2/5/2008

Collections to Begin at ProHEALTH Facility by End of First Quarter

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced receipt of a provisional license for comprehensive tissue procurement services for the collection of adult stem cells from the New York State Department of Health for the ProHEALTH Care Associates, LLP stem cell collection facility. ProHEALTH Care Associates is a multi-specialty network of over 100 physicians serving over 500,000 patients located in Long Island. ProHEALTH has gained particular renown by becoming the official medical provider of major regional sports franchises and events including the NY JETS, the NY Islanders, and the US Open Tennis Championships.

Robin Smith, MD MBA, NeoStem's Chairman and Chief Executive Officer stated: "The licensing of this facility is a milestone in our development. We have spent the past year signing agreements with collection centers and development groups to position us for revenue growth in 2008. We will now begin to benefit from our achievements. ProHEALTH is one of the largest and most prominent multi-specialty practices in the NY metropolitan region.

Dr. David Cooper, Chief Executive Officer of ProHEALTH, said: "This alliance is a testament to our commitment to provide our patients with the leading edge of medical technology. We believe NeoStem's proprietary methodology for collecting and storing autologous adult stem cells will give patients in our community the ability to take advantage of stem cell therapies offered today, as well as new therapies in development."

Dr. Smith added: "We anticipate the opening of additional collection facilities in 2008 and we will continue to build out our nation-wide network of collection centers. We are executing on our business plan and promoting the health and welfare of those individuals who chose to donate their own stem cells and store them with us."

About ProHEALTH

ProHEALTH Care Associates, LLP is the largest multi-specialty practice in New York State, with over 100 physicians caring for over 500,000 patients. ProHEALTH Corp. manages the LLP, as well as the ProHEALTH Ambulatory Surgery Center, all located in Lake Success, N.Y.

About NeoStem, Inc.

NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer, 212-584-4180

rsmith@neostem.com

http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
2. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
3. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
4. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
5. BioElectronics Announces Canadian Retail Product Launch
6. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
7. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
8. NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment
9. Remergent(R) Announces the Launch of Four New Products Pioneers of DNA Repair Expand Anti-Aging Line
10. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
11. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):